The Model
UK-based editorial site publishing source-cited research on peptide therapy (BPC-157, TB-500, CJC-1295, Ipamorelin, semaglutide and others). Connects US customers to a curated panel of licensed telehealth peptide clinics (cash-pay) plus a small set of compliant direct vendor affiliates. Monetised through flat-fee marketing-services retainers from telehealth clinics, direct vendor affiliate commissions, and newsletter sponsorship.
This is NOT a vendor. We don't sell peptides. The vendor seat is under live federal enforcement pressure — confirmed cases include Paradigm Peptides / Amino Asylum (Matthew Kawa + Jennifer Stechkober guilty pleas, US District Court Northern District of Indiana, December 10 2025; sentencing July 30 2026) and Peptide Sciences (voluntary closure March 6 2026 under FDA pressure, no charges filed). The Tailor Made Compounding SARM-distribution case ($1.79M forfeiture, DOJ EDKY) sits adjacent as a precedent for unapproved-drug distribution via the compounding-pharmacy channel. We are the information layer — different seat, different risk profile.
Why Now — The Window
- 23 April 2026: FDA removed 12 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-c, KPV, Semax, Epitalon, AOD-9604 and others) from Category 2 "do not compound."
- 23–24 July 2026 PCAC meeting: reviews them for formal addition to the legal 503A compounding list. Removal ≠ approval — but it reopens the licensed-compounding pharmacy channel via prescription.
- The "research use only" vendor model is being criminalised in parallel. The reclassification narrows their air cover, doesn't protect them.
- UK has no equivalent reform pending (MHRA seized £45m of illegal medicines in 2025). Waiting for UK = waiting for nothing.
- Search interest is climbing now. Sites that rank in June–July 2026 capture the wave. Sites that try to rank in August are too late.
The window is real but it's not the window most people think it is. The opportunity isn't "be a vendor before July." Vendors are getting raided now. The opportunity is to own the information layer before the demand wave — the search interest spike post-PCAC decision.
Revenue Stack — Priority Order
1. Telehealth Lead-Gen — Durable Revenue (Months 3–6+)
- Structure: Flat monthly marketing-services retainer with 2–3 licensed US telehealth peptide clinics. NOT per-prescription commission (Anti-Kickback Statute exposure even in cash-pay contexts).
- Pricing: £500–£1,500/mo per clinic retainer, OR £50–£150 per qualified consult booked (flat fee).
- Target: 1 signed clinic by Month 4–5, 2–3 by Month 6.
- Run-rate at Month 6 (target): £2,500–£4,500/mo from this lane.
2. Direct Vendor Affiliate — Bridge Cash (Months 1–6)
- Programmes: Apollo Peptide Sciences (20% tiered, AOV $150+), GLP-1 Research Lab (30%), Amino Club (20% first + 10% recurring), Onyx Biolabs (10%).
- No affiliate network mediation — all direct (Refersion or custom). Partner registers under their name.
- Conversion math: 1,000 organic visitors/mo × 3% conv × $200 AOV × 20% commission = $1,200/mo per 1K traffic.
- Target Month 6 traffic: 5–10K/mo organic = $6,000–$12,000/mo affiliate revenue.
3. Email List — The Long-Term Asset
- beehiiv newsletter. Architect voice — independent UK research desk covering US peptide regulation.
- Lead magnet: "What the July 2026 FDA Decision Means for Peptide Buyers" — high-intent capture.
- Monetisation: sponsored placements from compliant operators at 5K+ subscribers.
- Even if site monetisation degrades post-Feb 2027, list is a portable asset.
NOT in the stack
- Paid ads. Google + Meta ban peptide advertising at category level. Native (Taboola / Teads) only after Month 4 with test budget — not Day 1.
- Selling peptides ourselves. The DOJ is climbing the supply chain.
- GLP-1 telehealth comparison. Higher volume but saturated (Hims / Ro / Henry Meds dominated). Mention in content, don't centre the venture on it.
Venture Roles + Capital Required
Three seats exist on this venture. the operator sits in the editorial / research / build seat (already in place). The supply-side operator seat and the operational-lane seat are open; two people in the conversation map naturally onto them. Equity intent: equal partnership where someone fills a full seat with foundational contribution; specific terms set in conversation when seats are filled.
Editorial / Research / Build seat — CHORUS (Isa)
Known capability — in place from Day 1.
- Research, site build, editorial content
- SEO content engine + automation
- Regulatory monitoring (FDA PCAC, DOJ tracking)
- Brand, voice, infrastructure
- Entity, accounting, ongoing IP
- ~5 hrs/week ongoing
Supply-side operator seat — open
Patrick identified as profile match for the operator role on this venture, as his Bridge-family contribution extends naturally here. Conversation TBD.
- US telehealth clinic BD — Holt Law-style cold outreach + warm intros if existing relationships
- Compounding pharmacy landscape insight
- Adjacent industry network — direct affiliate vendor relationships
- ~10 hrs/week operational
Operational-lane seat — open
Venture was prompted by Keys; an operational-lane fit (e.g. newsletter + email funnels) is a natural role if he's interested. Conversation TBD.
- Newsletter / email-funnel ownership end-to-end (beehiiv, sequences, sponsored slots)
- OR community ops lane (Reddit, Discord, peptide-curious forums)
- Lane fully owned by seat-holder — CHORUS provides stack template if useful
- ~5–10 hrs/week operational
Capital required (facts of what's needed)
| Tranche | Range | Trigger |
|---|
| Phase 1 — launch (Month 1) |
£1,800–£2,800 |
Entity formation (Companies House £50), domain (£10), ICO data protection fee (£52), business email (£12–£70), basic UK ad-law review (£1,500–£2,500), Ahrefs Starter 3mo (£87), buffer (£200). Deploys before any telehealth retainer conversation. |
| Phase 2 — ramp (Month 3+) |
£4,500–£9,000 |
US healthcare attorney — AKS structure review for telehealth retainer contracts (£4,000–£8,000, can be consolidated with Ibogaine Bridge legal engagement to save £4K–£8K), native ad test budget (£500–£1,500), US LLC contingent formation (£0–£400 if a US-deal demands it). Gate-tied to clinic-pipeline traction. |
| 6-month total |
£6,300–£11,800 |
Funding source TBD. Capital-recovery-first waterfall would apply to whoever funds each tranche — funder recovers outlay off the top before profit distribution. Standard structure; specifics set when funder confirmed. |
Unit costs sourced May 2026 — see canvas methodology section.
Editorial drawn-line — what the venture will NOT do
- Never sell peptides. Information layer + telehealth referral + select compliant vendor affiliate only.
- Never make therapeutic claims. No "BPC-157 cures X." Source-cited journalism only.
- Never recommend a vendor without third-party COA verification.
Suggested role-fits — Patrick + Keys (not yet engaged)
Two people in the conversation history map onto the two open seats. Suggestions only — neither has yet seen this brief. Equity terms set at the table.
Supply-side operator seat
Patrick — profile-matched, conversation TBD
Patrick's Mexico pharma middleman background extends naturally into the peptide telehealth and compounding pharmacy landscape. He'd be the natural Bridge-family operator across Ibogaine + 5-MeO/Ayahuasca + Peptide rather than a single-venture seat. Equity intent: equal partnership on Bridge ventures where he fills the operator role — same 50/50 spirit as Ibogaine Bridge — adjusted for the additional operational-lane seat on this venture.
Operational-lane seat
Keys — possible newsletter / community ops fit
Keys prompted the peptide research independently. An operational lane he runs end-to-end (newsletter + email funnels is the natural fit) gives him a defined seat in the venture he set in motion. Alternative lanes (Reddit/Discord community ops; paid acquisition Month 4+) are also possible. Equity for an operational-lane seat is typically smaller than a full operator/build seat, with vesting tied to deliverables (subscriber growth, sequence performance, sponsored revenue).
Clean-exit alternative if a lane-seat doesn't fit: a small finder's-fee revenue share (e.g. 2% of first-year gross, capped) honours the original prompt without cap-table entanglement.
These are observations on profile fit, not offers. Conversations bring final structure.
Entity + Payments (UK-Based, Information Layer Only)
This venture is not a vendor — it sells marketing/information services, not peptides. No high-risk processor needed. UK Ltd carries everything; US-side requirements (AKS structure review, contingent US LLC) deploy in Phase 2 only when traction justifies.
| Layer | Choice | Cost |
|---|
| Entity | UK Limited company. Directorship + share structure set when seats are filled. | £50 incorporation + £50/yr confirmation (Feb 2026 fees) |
| ICO data protection registration | Required for any UK business handling personal data (lead capture, email list). | £52/yr (Tier 1) |
| Business bank | Starling Business or Tide. USD inbound via SWIFT. | Free |
| Business email | Namecheap Private Email or Google Workspace Business Starter. | £12–£70/yr |
| Payment processor | Stripe UK on UK Ltd. Handles USD invoicing + affiliate payouts. Site is informational, not a peptide storefront — no high-risk flag. | 1.5% + 20p / UK card txn |
| Affiliate payouts | All major peptide vendor programmes pay UK Ltds. File W-8BEN-E once at signup → zero US withholding tax. | Free |
| Telehealth retainer invoicing | Stripe Invoicing or Wise Business for cleaner USD→GBP FX (Wise saves ~1.5% vs Stripe FX). | Wise free; FX at mid-market |
| Accounting | FreeAgent (free with Starling) or Xero from Month 4. | £0 → £15/mo |
AKS structure review — Phase 2 essential. Telehealth referral contracts touch US healthcare regulation. Specialist legal review (Holt Law or LumaLex Law) flat-fee market norm $5,000–$15,000 (≈£4,000–£12,000) for AKS + medical-tourism scope. Required before signing the first telehealth retainer. If consolidated with Ibogaine Bridge's same engagement (single review covering both Bridge family entities), saves £4,000–£8,000 across the family. If a US LLC counterparty is demanded by a specific deal, form via Stripe Atlas ($500) or Firstbase ($399). Defer the US LLC decision until Month 3.
6-Month Operating Plan
Month 1
Build + foundation. Week 1: brand + domain + entity decisions. Partnership terms documented. Affiliate accounts applied. Specialist legal review booked. Week 2: site build (Astro). 5 cornerstone articles drafted. Week 3: site live. SEO technicals locked. Email list live. Week 4: 3 more articles. Telehealth clinic outreach list drafted (50 targets).
Month 2
Content + outreach. 8–10 new articles. Cold outreach to telehealth clinics. Reddit / Discord presence begins. First affiliate commissions expected.
Month 3
Pipeline build. Assuming cold-outreach (no warm clinic intros from operator seat at start): realistic to have 5+ qualified clinic conversations active, 1 in late-stage. First telehealth retainer realistic by Month 4–5. Warm intros from operator seat owner would accelerate this. Site at 1–3K visitors/mo. Newsletter 500+ subs.
Month 4
July PCAC decision — critical content sprint. 1 week pre-PCAC: live coverage page, FAQ, post-decision rapid-response articles (drafted in 3 variants — approve / defer / reject). Newsletter goes live with PCAC analysis 24h post-meeting. Expected 3–5× organic traffic spike. Convert to email list growth (target +2,000 subs in 30 days).
Month 5
Monetisation lift. Second telehealth retainer signed. Native ad test budget (£500 across Taboola/Teads) on top 3 articles. Sponsored newsletter slot opens.
Month 6
Decision point. Run-rate review. Continue as 3-year compounding asset, sell to industry operator (peptide telehealth co. with growth budget), or wind down to email-list-only.
Honest Numbers
| Scenario | Month 6 monthly run-rate | 6-month gross |
|---|
| Bear | £1,500–£3,000 | £4,000–£8,000 |
| Base | £3,000–£6,000 | £8,000–£15,000 |
| Bull | £8,000–£15,000 | £25,000–£40,000 |
| Sale exit (Month 6–9) | — | £30,000–£80,000 lump |
Smaller than ibogaine bridge (which has 10–20× the per-conversion economics), but the venture pair compounds via shared audience and shared infrastructure. Bear-case is still cash-positive within 6 months.
Risks
HIGHPCAC rejects in July. Probability ~10%. Mitigation: pre-written articles for all three outcomes (approve / defer / reject). Pivot harder to international / research framing. Affiliate revenue persists.
MEDFDA expands Import Alert 66-78 → kills US-bound affiliate orders. Already happened once March 2025. Mitigation: telehealth referral revenue insulated. Pivot weight if needed.
MEDPayment processor (Stripe) deplatforms site. Lower risk because we're information services, not product vendor. Mitigation: Form US LLC if needed. High-risk gateway alternatives (Easy Pay Direct, PaymentCloud).
MEDAKS exposure on telehealth referrals. Low if structured correctly. Mitigation: flat retainer never per-prescription. US legal review pre-contract.
MEDGoogle YMYL (Your Money Your Life) search penalty. Mitigation: E-E-A-T compliance — real author bio, citation-heavy, no health claims, conservative tone.
MEDPartner walks Month 3. Mitigation: partnership terms include 30-day notice + content-engine handoff clause. Site survives on CHORUS-side autopilot for 60 days.
Adjacent Hooks (Parked Unless 6-Month Review Goes Bull)
- UK-side equivalent site if MHRA opens a consultation (currently no signal)
- Compounding pharmacy directory as a vertical product — could be sold standalone
- B2B newsletter for telehealth peptide clinics — operator-facing, premium subscription model
- Proven Longevity citation reverse-link — once the bridge site has authority, Proven Longevity content can cite it as a third-party research desk (one-way, never reverse)
Open Decisions
- Brand name — three candidates pre-launch. Open input from anyone joining the venture.
- Supply-side operator conversation — engage Patrick on the Bridge family operator seat across Ibogaine + 5-MeO/Ayahuasca + Peptide (this venture sits inside that conversation). Equity terms at the table.
- Operational-lane conversation with Keys — whether a defined lane (newsletter / community ops) is interesting to him, or whether a finder's-fee revenue share is the cleaner fit. His call.
- Phase 1 capital sourcing (£1,800–£2,800) — funder TBD. Single decision.
- Phase 2 capital sourcing (£4,500–£9,000) — gate-tied to telehealth retainer pipeline traction. Triggered Month 3+.
- Consolidated Bridge-family legal review — single US healthcare attorney engagement covering Ibogaine + Peptide entities saves £4K–£8K vs two separate reviews. Schedule the discovery call Month 2.
- Newsletter stack ownership — operational-lane seat holder builds or runs a CHORUS-provided template, their choice.
- Exclusivity — parties on the cap table agree not to launch competing peptide info ventures for 24 months post-exit. Standard clause.